How Divamics' AI Platform is Revolutionizing Drug Discovery for Metabolic Diseases
Divamics' AI and Molecular Dynamics Achievements
In a groundbreaking development, Divamics, an innovator in AI-driven drug discovery, has revealed its significant contributions to the advancement of therapeutics aimed at metabolic diseases. This progress is primarily supported by their sophisticated AI and molecular dynamics platform, which has played a pivotal role in crafting a novel drug that targets obesity. The drug, dubbed BGM1812, is a dual AMY3R/CTR receptor agonist that showcases the efficacy of Divamics' technology. This achievement was highlighted in the latest issue of the Journal of Medicinal Chemistry, where this cutting-edge approach was celebrated.
Collaborations for Success
Divamics has continuously empowered its partners to enhance their drug discovery pipelines, and the design of BGM1812 stands as a testament to this commitment. Through advanced computational methods, Divamics has optimized peptide interactions to achieve a superior binding affinity for the targeted receptors. Preclinical studies have already indicated a remarkable achievement with BGM1812 demonstrating a 50% increase in in vitro potency, alongside major improvements in metabolic profile and weight loss in in vivo settings.
Mechanistic Insights from AI and Molecular Dynamics
At the core of Divamics' success lies its ability to provide a comprehensive mechanistic understanding of drug-receptor interactions at an atomic level. One notable example is the mutation of Ile(Me)24 to Gly(Me)24, which resulted in improved anti-aggregation features for the drug. The AI-guided molecular dynamics (MD) simulations uncovered the significance of hydrophobic residues that formed a critical “hydrophobic cage” with the receptor, which is key to stabilizing the overall molecular structure. Additionally, strategic alpha-carbon methylation, influenced by Divamics' AI algorithms, played a crucial role in leading to the successful synthesis of BGM1812.
Track Record of Success
Divamics has had a successful history of contributing to multiple drug candidates. Apart from BGM1812, their technology facilitated the development of BGM0504, which is currently undergoing Phase III clinical trials since 2024. The profound impact of Divamics' AI and molecular dynamics technology illustrates the company's expertise in propelling forward the development of therapeutics aimed at metabolic conditions.
A New Paradigm in Drug Discovery
As noted by Dr. John Zheng, CEO of Divamics, their partnerships, including those with Brightgene, underscore the potential of their platform to redefine how companies can tackle previously deemed 'undruggable' targets. The collaboration has already yielded promising results with the publication of BGM1812 and the advancement of BGM0504 into clinical testing. This technology is not merely accelerating discovery; it is empowering pharmaceutical partners to bring forth high-quality therapeutic leads more efficiently than ever.
Future Commitment
Divamics remains dedicated to its mission of providing cutting-edge AI and molecular dynamics capabilities that will continue to enhance the landscape of global drug development. As the need for novel therapeutics increases, the company's ongoing innovations in AI-driven drug discovery exemplify the future of effective treatment approaches for metabolic diseases.
In summary, Divamics is at the forefront of leveraging AI and molecular dynamics in drug development, setting a new standard in the acceleration of innovative therapies for metabolic diseases.